Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid antibody syndrome

M D Lockshin1

  • 1Extramural Program, National Institute of Arthritis and Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, Maryland.

Rheumatic Diseases Clinics of North America
|February 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus.

Lupus·2018
Same author

Functional Magnetic Resonance Imaging of Working Memory and Executive Dysfunction in Systemic Lupus Erythematosus and Antiphospholipid Antibody-Positive Patients.

Arthritis care & research·2016
Same author

Assisted reproductive technology in SLE and APS.

Lupus·2014
Same author

Site differences in mild cognitive dysfunction (MCD) among patients with systemic lupus erythematosus (SLE).

Lupus·2012
Same author

Antiphospholipid: to test, or not to test, that is the question.

International journal of clinical practice·2012
Same author

APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking.

Lupus·2012

Antiphospholipid syndrome (APS) is distinct from SLE, requiring refined diagnostic criteria. For autoimmune APS, the antigen is likely a phospholipid-beta 2 glycoprotein I complex, not just phospholipid alone.

Area of Science:

  • Rheumatology
  • Immunology
  • Clinical Medicine

Background:

  • Antiphospholipid syndrome (APS) is increasingly recognized as a distinct entity separate from Systemic Lupus Erythematosus (SLE).
  • Current diagnostic criteria for APS require refinement in both clinical manifestations and serological definitions.
  • The precise nature of the antigen in autoimmune APS is debated, with emerging evidence suggesting a complex rather than isolated phospholipid.

Purpose of the Study:

  • To clarify the antigenic target in autoimmune antiphospholipid antibodies (aPL).
  • To review the current state of treatment options for Antiphospholipid Syndrome.
  • To highlight the need for improved diagnostic quantitation in APS.

Main Methods:

  • Review of existing literature on antiphospholipid syndrome.

Related Experiment Videos

  • Analysis of serological findings related to phospholipid and beta 2 glycoprotein I.
  • Evaluation of published treatment trials for APS.

    • Main Results:

    • Evidence suggests that for autoimmune-induced aPL, the antigen is a complex of phospholipid and beta 2 glycoprotein I, not solely phospholipid.
    • Few treatment trials for APS have been published to date.
    • Available data indicate that antiplatelet or anticoagulant therapies may be more effective than immunosuppression.

    Conclusions:

    • Antiphospholipid syndrome is a distinct clinical entity requiring further refinement of diagnostic standards.
    • The primary antigen in autoimmune APS is likely a phospholipid-beta 2 glycoprotein I complex.
    • Current treatment evidence favors antiplatelet or anticoagulant strategies over immunosuppression for APS management.